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A high-fat diet (HFD) induces metabolic disease and
low-grade metabolic inflammation in response to
changes in the intestinal microbiota through as-yet-
unknown mechanisms. Here, we show that a
HFD-derived ileum microbiota is responsible for a
decrease in Th17 cells of the lamina propria in axenic
colonized mice. The HFD also changed the expres-
sion profiles of intestinal antigen-presenting cells
and their ability to generate Th17 cells in vitro.
Consistent with these data, the metabolic phenotype
was mimicked in RORgt-deficient mice, which lack
IL17 and IL22 function, and in the adoptive transfer
experiment of T cells from RORgt-deficient mice
into Rag1-deficient mice. We conclude that the mi-
crobiota of the ileum regulates Th17 cell homeostasis
in the small intestine and determines the outcome of
metabolic disease.
INTRODUCTION
A major feature of type 2 diabetes (T2D) is the inability of periph-
eral tissues to adequately respond to insulin (termed insulin
resistance). This metabolic disease is characterized by systemic
low-grade inflammation of liver, muscle, and adipose tissue (AT),
referred to as metabolic inflammation (Hotamisligil, 2006).
T2D can be induced in mice genetically or by a high-fat diet
(HFD), which also induces production of the inflammatory cyto-
kines, interleukin (IL) 1b, and TNFa and chemokine CCL2 in
mesenteric AT (MAT) (Weisberg et al., 2003). Moreover, AT infil-
tration by T and B cells increases the inflammatory state in obese
mice, leading to insulin resistance (Nishimura et al., 2009; Winer
et al., 2011). Loss-of-function experiments demonstrated an100 Cell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc.imbalance between regulatory and effector T cells which is
crucial in this inflammation (Feuerer et al., 2009).
Results from our laboratory (Cani et al., 2008) and others
(Turnbaugh et al., 2006) have demonstrated that obesity and
T2D are associated with an increase in the ratio of Firmicutes
to Bacteroidetes phyla in the gut microbiota. These changes
are associated with increased energy harvesting and upregula-
tion of genes implicated in hepatic lipogenesis and AT develop-
ment (Ba¨ckhed et al., 2004; Turnbaugh et al., 2006). Another way
in which changes in the gut microbiota might induce low-grade
inflammation is by modulation of the gut immune system (Atara-
shi et al., 2011; Ivanov and Littman, 2011), including cells of both
the innate (macrophages, dendritic cells, and innate lymphoid
cells) and the adaptive immune systems.
In the gut, CD4 T cells contribute to immunity by differentiating
into various subsets, notably inflammatory and regulatory cells
(Bollrath and Powrie, 2013; Shale et al., 2013). Th17 cells are the
most abundant CD4 T cells in mucosal tissues (Littman and Ru-
densky, 2010). They secrete two isoforms of IL17 (IL17A, IL17F)
and/or IL22,whichconferprotectionagainst fungi andpathogenic
bacteria. Th17 cell differentiation is mediated by the transcription
factor retinoid-related orphan receptor gamma t (RORgt) (Ivanov
et al., 2006), and induced by cytokines: TGFb1, IL6, IL1b and
IL21, and maintained by IL23 (Chewning and Weaver, 2014).
The development and maturation of the immune system is
influenced by gut microbiota (Hooper and Gordon, 2001; Som-
mer and Ba¨ckhed, 2013). Some commensal bacteria, such as
segmented filamentous bacteria (SFB), are necessary for gut
Th17 cell development (Gaboriau-Routhiau et al., 2009; Ivanov
et al., 2009). In contrast, Clostridium and Bacteroides fragilis
favor Tregs development (Atarashi et al., 2011; Round and Maz-
manian, 2010). We hypothesized that changes in the gut immune
system, in response to changes in gut microbiota, would be suf-
ficient to trigger metabolic disease like T2D. In this study, we set
out to test this hypothesis by analyzing the changes in intestinal
T cells induced by feeding mice with a HFD and demonstrated
their causal role through T cell adoptive transfer. We further
report evidences that dysbiotic ileummicrobiota impart changes
in intestinal innate immune and CD4 T cell homeostasis—
notably, a loss of Th17 cells. These changes precede the onset
of metabolic disease, and they are sufficient to induce glucose
intolerance and insulin resistance features of T2D.
RESULTS AND DISCUSSION
HFD-Induced T2D Impairs Intestinal Immunity
To investigate how the gut immune system is affected at the
earliest stages of diet-induced metabolic disease, we studied a
first animal model in which the mice were fed a fat-enriched, car-
bohydrate-free diet for 10 or for 30 days. After 10 and 30 days on
HFD, the mice were glucose intolerant and insulin resistant, but
their fasting glycemia levels were not different from that of normal
chow (NC)-fedmice (NC) (Figures 1Aand1B). The liver triglyceride
concentration was not different when compared to NC-fed mice
(seeFigureS1Aavailableonline)but lateraccumulatesat3months
of HFD (Burcelin et al., 2002). This animal model is also character-
ized by a strong lipotoxicity, since the mice are insulinopenic, as
shown in the fed state (Figure S1B). Consequently, the fed plasma
insulin/glucose ratio was reduced in the HFD-fed mice (Fig-
ure S1C). Due to this relative hypoinsulinemic state, the mice did
not gain significant weight during this short period of time,
although the HFD-fed mice had a higher fat/lean ratio than the
control mice (Figures S1D and S1E). However, over 3–6 months
the HFD-fedmice adapt to the diet and eventually gain significant
weight (Burcelin et al., 2002). Altogether, studyingmice fed a 72%
HFD avoids the confounding effects of obesity on glucose toler-
ance and insulin resistance. In contrast to previous reports (Bleau
et al., 2014), the subcutaneous AT and MAT mRNA levels for in-
flammatory cytokines (TNFa, IFNg, IL6, and PAI1) were not signif-
icantly different after 10 and 30 days on HFD when compared to
NC mice (Figures S1F and S1G). This is most likely due to the
fact that we studied the early onset of the disease, suggesting
that the metabolic inflammation observed by others could be
the consequence of hyperglycemia and excessive body weight
gain. This conclusion is further supported by our data since no
change in IL17A, IL17F, and IL22 mRNA levels was observed at
the onset of HFD-induced metabolic disease (Figures S1F and
S1G). To better define this issue, we quantified cell number from
the MAT and observed a slight increase of IL17-producing CD4
T cells (Th17) after 10 days on HFD when compared to NC mice
(Figure S1H). Foxp3-expressing regulatory T (Treg) cell number
was transiently decreased after 10 days on HFD mice when
compared to NC mice (Figure S1I). IFNg-producing CD4 T cell
number (Th1) was not affected by the HFD (Figure S1J). In sum-
mary,nomajor inflammatoryprocesswasobserved in theMATaf-
ter only 30 days on HFD. In the liver, a major site of HFD-induced
metabolic inflammation, mRNA levels of IL17A and IL17F were
increased from10daysofHFD (Figure S1K). Second, the number
of Th17 cells in the liver was increased after 10 days on HFD
and remained statistically elevated after 30 days on HFD
compared to NC mice (Figure S1L). Furthermore, Treg cell num-
ber was slightly decreased from 10 days on HFD when
compared to NC mice (Figure S1M), and Th1 cell number
decreased transiently after 10 days and returned to the same
level as NC after 30 days on HFD (Figure S1N). Eventually, the
p-NFkB to NFkB ratio was increased after 30 days on HFD (Fig-ure S1O). Altogether, we observed moderate inflammation in the
liver related to Th17 cells in response to the HFD at the onset of
metabolic disease. In the quest of a major tissue responsible for
the late development of tissue inflammation and consequently
metabolic disease, we evaluated changes in intestinal cytokine
production at the onset of metabolic disease. In the ileum and
in Peyer’s patches, IL22, IL17A, IL17F, and IL10 mRNA levels
were decreased in HFD (Figure S1P and S1Q) when compared
to controls. Similarly, in the MLN, IL17A and IL22 mRNA levels
decreased dramatically after 10 days and remained low after
30 days on HFD despite the slight increase of IFNg and PAI1
mRNA levels (Figure S1R). In the colon of HFD mice, the IL22
and IL10 mRNA levels were decreased, IL17A was not detect-
able, and no major change was noticed in IL17F despite a small
increase of IFNg and IL6 mRNA levels (Figure S1S). This sug-
gests a loss of IL17- and IL22-secreting cells, which is rather
a feature of a reduced inflammatory process. Since the most
dramatic changes in cytokine expression were in the ileum
rather than in the colon, we focused the rest of our study on
the small intestine (SI) and observed first, in the lamina propria
(the subepithelial layer) of the SI (SILP), that the proportion
and number of Th17 cells were decreased after 10 and
30 days on HFD when compared to the NC (Figures 1C and
1D). This is consistent with the reduction in IL17 mRNA levels
already mentioned (Figure S1P). We also found a decrease in
the proportion and number of RORgt-expressing CD4 T cells af-
ter 30 days on HFD (Figures 1E and 1F). Second, we found that
Tregs decreased in proportion and number in the SILP after
30 days on HFD (Figures 1G and 1H). Third, we quantified the
Th1 cells and found their proportion increased in the SILP after
30 days on HFD compared to the NC, although both contained
a similar number of Th1 cells (Figures 1I and 1J), which may be
explained by the decrease in total T cell number (Figure S1T).
Therefore, our data show a moderated increased proportion of
Th1 cells at the onset of the disease which remains further sus-
tained later, as reported elsewhere (Luck et al., 2015). Impor-
tantly, our present data further show a reduced number of intes-
tinal Th17 cells at the onset which defined a low state of
inflammation, whereas recent data show that HFD induced an
increased intestinal inflammatory state at later stage of the dis-
ease. Altogether, both sets of data suggest that metabolic dis-
ease is the consequence of first a reduced intestinal inflamma-
tion, as characterized by a low number of Th17 cells. Second,
intestinal inflammation develops at a late stage of the disease
(Luck et al., 2015).The origin of the late-stage intestinal inflam-
mation is yet unknown.
Moreover, no Th2 cells (IL4-producing CD4 T cells) were de-
tected (data not shown), andwe foundnochanges inTh17, Tregs,
Th1, and Th2 cells in the intraepithelial layer (IEL; the layer facing
the lumen) (Figures S1U–S1W) or in the MLN (Figures S1X–
S1Z).To rule out any contribution of MLN, we surgically ablated
those lymph nodes. These mice developed glucose intolerance
to the same extent as sham-operated mice (data not shown),
suggesting that the changes observed were specific to the SILP.
Taken together, T cell subset analyses indicate a loss of Th17
cells and Tregs specifically in the SILP at the onset of metabolic
disease. We then repeated these findings in another model of
metabolic disease associated with obesity, high-fat high-carbo-
hydrate diet (HFHCD) fed mice. After 1 month of a HFHCD, miceCell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc. 101
Figure 1. The HFD Induces Changes in Intestinal Immunity before the Onset of Insulin Resistance
(A–J) Mice were fed a NC or a HFD 72% for 10 or 30 days.
(K–N) Mice were fed a NC or a HFHCD (45%) for 10 or 30 days.
(A) IPGTTwas performed onWTmice fedwith a NC or fed a HFD for 10 (HFD d10) or 30 days (HFD d30). The glycemic index (mM/min) was calculated as described
in the Experimental Procedures. Graphs show mean ± SEM; n = 5 mice/group; data are from one experiment out of three.
(legend continued on next page)
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became glucose intolerant (Figure S2A) and obese (Figures S2B
and S2C). The number of T cells in the SILP was also reduced af-
ter 10 and 30 days on the HFHCD (Figure S2D). The number of
Th17 and Treg cells was also decreased in the SILP after 10
and 30 days on the HFHCD (Figures 1K–1M) and the number
of Th1 unaffected (Figure 1N).
Altogether, the above data show that a HFD, irrespective of the
presence of carbohydrate, induces a strong specific decrease in
the number of Th17 cells within the SILP which may lead to the
onset of metabolic disease. It is noteworthy that T2D patients
are more sensitive than normal to intestinal infections with path-
ogens like Candida guilliermondii, further suggesting that they
may have impaired Th17 cells (Khovidhunkit et al., 2009; Lutsey
et al., 2009; Maceˆdo et al., 2010). Consistent with this observa-
tion in human subjects, it was shown that HFD-fed rodents were
more prone to Candida albicans infection than controls (Lefe`vre
et al., 2010). This was attributed to a shift of cecal APCs/macro-
phages toward an anti-inflammatory profile in the HFD-fed mice.
IL17/RORgt-Deficient CD4 T Cells Induce T2D
and Obesity
To determine whether the reduced RORgt/Th17 seen in the
SILP in response to theHFD is linked to theonsetofmetabolic dis-
ease, we investigated mice lacking RORgt. When 20-week-old,
RORgt knockout (RORgt/) mice fed a NC diet became glucose
intolerant, hyperinsulinemic, and slightly insulin resistant (Figures
2A–2C) and gained more weight than the WT mice (Figures 2D
and 2E) No statistic differences in food intake and hepatic triglyc-
eride concentration were detected (Figures 2F and S3A).
Of note, RORgt/ mice fed the HFD rapidly lost weight and
died within one month (data not shown). This could be due to a
deleterious effect of the lipotoxicity induced by the HFD. In addi-
tion to the lipotoxicity, the changes in gut microbiota induced by
the HFD (Cani et al., 2008) could lead to an immunological stress
in RORgt/ mice, which lack secondary lymphoid organs,
which has previously been associated with excessive bacterial
burden leading to death (Lochner et al., 2011). This important
phenotype is still under investigation. We then studied heterozy-
gousRORgt+/mice. First, 12-week-old heterozygousRORgt+/
mice were slightly glucose intolerant (Figure 2G) and obese (data
not shown). Insulin sensitivity was slightly reduced when
compared to WT mice (Figure 2H), suggesting that the lack of
one allele of RORgt is a risk factor for metabolic disease. Sec-
ond, we challenged the mice with a HFD (72% fat). After
30 days, the RORgt+/ mice became more glucose intolerant,
had more fat mass and were insulin resistant than WT mice (Fig-
ures 2H–2J). The difference in fat mass accumulation is most
likely due to a slight increase in food intake. However, we cannot
rule out that reduced energy expenditure could also be involved,
since the deficient mice were slightly insulin resistant. This latter
trait is often associated with reduced energy expenditure. Alto-
gether, RORgt-deficient mice develop metabolic disease.(B) Glucose infusion rate (GIR) was calculated during euglycemic hyperinsulinem
(C–N) SILP leukocytes (CD4+TCR+CD45+ cells) from mice fed a NC diet, a HFD,
proportion of CD4 T cells and is represented in histogram (n = 5 mice/group; data
and K) of IL17+ CD4 T cells after stimulation. (E, F, and L) Proportion (%) (E) and nu
and number (#) (H andM) of Foxp3 Treg cells. (I, J, and N). Proportion (%) (I) and n
SEM; Different superscript letters (a,b) in each graph indicate data statistically dTo determine whether the metabolic phenotypes of the
RORgt-deficient mice correlated with the status of their CD4
T cell subsets in the SILP, we analyzed T cell populations. As ex-
pected in RORgt/ mice, no Th17 cells were detected (Ivanov
et al., 2006), whereas Tregs and Th1 cells were found in similar
proportions (Figures 2K–2M). In RORgt+/mice fed NC, the pro-
portion of Th17 and Treg cells in the SILP was reduced by about
half when compared to WT mice (Figures 2N and 2O).
Conversely, the proportion of Th1 cells was higher in the
RORgt+/ mice fed NC than in WT mice. No additional effect of
the HFD was observed (Figure 2P). Th2 cells were not detected
in the SILP of RORgt+/ mice (data not shown). Together, the
decrease of IL17/RORgt CD4 T cells in the SILP is strongly asso-
ciated with the development of T2D, confirming the importance
of these cells in the control of metabolic disease.
To demonstrate that the absence of IL17/RORgt in T cells
rather than in innate lymphoid cells is crucial in the development
of metabolic disease, Rag1/ mice were injected with splenic
T cells isolated from RORgt/ or WT mice. The Rag1/ mice,
which lack T and B cells, were injected with T cells from
RORgt/ mice and were more glucose intolerant, insulin resis-
tant, and hyperinsulinemic (Figures 2Q–2S) than did those
injected with T cells fromWTmice. In addition, the decreased in-
sulin responsiveness was supported by the reduced phosphor-
ylation of Akt andGSK3 in the liver andmuscles (EDL and soleus)
(Figures 2T–2V). Furthermore, the Rag1/ mice injected with
RORgt/ T cells gainedmoreweight than the control, but no dif-
ferences in food intake and hepatic triglyceride accumulation
were observed (Figures 2W–2Y and S3B).
Altogether, this set of data further suggests that IL17/RORgt
T cells are key players in the control of metabolic disease, ruling
out other IL17- and IL22-producing cells such as innate lymphoid
cells and gd T cells. In agreement with our findings on RORgt-ex-
pressing cells, a recent study demonstrated the role of IL22 in the
control of metabolic disease through its positive action on AT,
liver, and muscle metabolism. This study suggests a role for
the immunity of the colon in the control of metabolism (Wang
et al., 2014). In our study, we further suggest that IL17, in the con-
trol of metabolism, originates from RORgt CD4 T cells of the
small intestine, rather than of the colon. These differences could
also be related to the the HFD exposure, since this decrease of
the number of RORgt/Th17 cells is observed as soon as the
onset of HFD-induced insulin resistance and glucose intoler-
ance. To further investigate this hypothesis, we performed a
gain of function by increasing IL17-expressing cells in the intes-
tine in HFD-treated mice, using dextran sodium sulfate (DSS)
(Figure S4A). This experimental procedure generates an intesti-
nal inflammation through a mechanism involving an increased
gut permeability to bacteria, which is associated with an
elevated IL17 production (Konieczna et al., 2013). Pretreatment
of mice with DSS prevented HFD-induced glucose intolerance
and insulinopenia (Figures S4B and S4C). Body weight gainic clamp in NC or HFD-fed mice (n = 8 mice/group).
or a HFHCD were analyzed by flow cytometry. The boxed population shows
from 1 experiment out of 4). (C, D, and K) Proportion (%) (C) and number (#) (D
mber (#) (F and L) of SILP RORgt+ CD4 T cells. (G, H, and M) Proportion (%) (G)
umber (#) (J and N) of IFNg+ CD4 T cells upon stimulation. Graphs showmean ±
ifferent with p > 0.05.
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and food intake remained unchanged (Figure S4D; data not
shown). The prevention from HFD-induced glucose intolerance
was associated with an increase of IL17A and IL22 mRNAs in
the ileum, as expected (Figures S4E and S4F). However, we
cannot rule out an independent role of a change in gutmicrobiota
induced by the DSS treatment, which could also increase the
number of Th17-producing cells and be responsible for the pre-
vention of HFD-induced metabolic disease. Altogether, this set
of data suggests that the maintenance of a steady intestinal in-
flammatory tone prevents from the later impact of a risk factor,
such as HFD, on metabolic disease. This conclusion is sup-
ported by a study showing that mice deficient in the TGFb-acti-
vating kinase TAK1 spontaneously develop inflammation of the
ileum and are resistant to metabolic disease (Kang et al.,
2011). Likewise, the incidence of metabolic disease is lower in
humans with intestinal inflammatory syndrome than it is in the
general population (Brown et al., 2012). Overall, these experi-
ments in which Th17 cell function is either lost (as in RORgt/
mice) or gained (as in inflammatory conditions) demonstrate
that intestinal RORgt/Th17 cells play an important role in the
onset of HFD-induced metabolic disease.
HFD Changes Intestinal Microbiota which Affects
Intestinal IL17/RORgt-Expressing CD4 T Cells
It is well accepted that the HFD modulates the gut microbiota
(Turnbaugh et al., 2006) and leads to the development of meta-
bolic disease. To evaluate whether this microbiota dysbiosis is
responsible for the loss of intestinal Th17 cells in response to
the HFD, we first monitored the changes in the gut microbiota
by16S rRNAgenesequencingof the ileummucosa.Concomitant
with the loss of Th17 cells, themicrobial composition of the ileum
mucosa after 10 and 30 days on HFD changed drastically when
compared to NC mice (Figure 3A). This result was confirmed in
feces (data not shown). The relative abundance of the Porphyro-
monadaceae decreased after 10 days, whereas that of Bacteroi-
daceae and Comamonadaceae increased (Figures 3B, S5A, and
S5B) and theproportion of theHelibocateraceae andPeptostrep-
tococcaceae increased after 30 days on HFD. Additionally, weFigure 2. RORgt-Expressing Th17 Cells Protect against Glucose Intole
(A) IPGTT was performed on 20-week-old WT (n = 5) and RORgt/ (n = 3) mice
(B) Plasma insulin was quantified by ELISA from fasted or fed 20-week-old ROR
(C) Glucose infusion rate (GIR) was calculated during a clamp in 20-week-old RO
(D) Body weight gain of RORgt/ (n = 3) and WT (n = 5) mice fed NC.
(E) Fat/lean ratio was calculated from EchoMRI analysis on 20-week-old RORgt
(F) RORgt/ (n = 6) and WT (n = 5) mice food intake was measured during 30 h
(G) IPGTT was performed on 12-week-old NC-fed WT (n = 5) and RORgt heter
calculated.
(H) Glucose infusion rate (GIR) was calculated during a clamp in RORgt+/ andWT
for 30 days.
(I) IPGTT was performed on HFD-fed (for 30 days) WT (n = 5) and RORgt+/ (n =
(J) Fat/lean ratio was calculated from EchoMRI analysis on RORgt+/ (NC n = 3;
(K–P) Proportion of IL17 (K andN) and IFNg (M and P)-producing CD4 T cells and F
WT, RORgt/, and RORgt+/ mice fed a NC or a HFD (n = 5 mice/group).
(Q–Y)Rag1/micewere injectedwith T cells fromRORgt/mice (Rag1/+ LTR
was performed and glycemic index (mM/min) was calculated (n = 9mice/group; da
procedure. (S) Plasma insulin was quantified from fasted or fed mice. (R and S) n =
of Akt (T) and GSK3 (U) was quantified bywestern blot in liver, EDLmuscle, and so
weight gain after T cell transfer expressed in %. (X) Fat/lean ratio was calculate
(X and Y) n = 5 mice/group; data are from one representative experiment out of
(A–Y) All values are means ± SEM; Different superscript letters (a, b) indicate datalso confirmed changes in ileum microbiota associated with the
decrease of IL17/RORgt cells with the HFHCD-fedmousemodel
(Figures 1K, 1L, S5C, and S5D).
To investigate that the decreased number of intestinal Th17
cells observed in HFD-induced metabolic disease was due to
the intestinal dysbiosis itself and not to the fat in the diet, we
treated HFD-fed mice daily by oral gavage with a mixture of pre-
biotic and probiotic. As expected, this synbiotic treatment (Ko-
lida and Gibson, 2011) profoundly affected the ileum mucosa
microbiota (Figures 3C and 3D). 16S rRNA gene sequencing
analysis revealed that HFD-fed mice given the synbiotic treat-
ment had a microbiota distinguishable from the other groups
(Figure 3C). We observed an increase in Sutterellaceae, Corio-
bacteriaceae and Bacteroidaceae, and a decrease in Lachno-
spiraceae in comparison to WT NC and HFD mice (Figures 3D,
S5A, and S5B). Furthermore, the synbiotic treatment reversed
the decrease in Porphyromonadaceae and the increase in Pep-
tostreptococcaceae and Comamonadaceae, seen in HFD
mice. The change of microbiota, after 30 days of HFD, in synbi-
otic-treated mice was associated with an improved glucose
tolerance (Figure 3E) and fat/lean ratio (Figure S5E). Similarly, in-
sulin secretion wasmodestly improved along with the normaliza-
tion of the plasma insulin to glycemia concentration ratio (Figures
S5F ans S5G), and insulin resistance was also reduced when
compared to HFD mice (Figure 3F). However, no significant dif-
ferences in food intake, body weight, and hepatic triglyceride
concentrations were induced by the synbiotic (Figures S5H–
S5J). The metabolic improvement due to synbiotic treatment
was associated with the prevention of decrease in numbers of
Th17 and Treg cells in the SILP, without affecting their Th1 num-
ber (Figures 3G–3I). Altogether, our results showed that synbiotic
treatment modulated the gut microbiota and provided some pro-
tection from the effect of 30 days HFD through improved glucose
tolerance and prevention of the loss of Th17 cells within the SILP.
Furthermore, the frequency of bacteria families, Porphyromona-
daceae, Peptostretococaceae, Comamonadaceae, and Bacter-
oidaceae correlates with the ileum IL17 and RORgt mRNA con-
centration (Figures 3J–3O). Importantly, Porphyromonasrance
fed with a NC; glycemic index (mM/min) was calculated.
gt/ (n = 5) and WT (n = 6) mice.
Rgt/ (n = 8) and WT (n = 8) mice.
/ (n = 3) and WT (n = 5) mice.
r.
ozygous (RORgt+/, n = 4) mice fed with a NC; glycemic index (mM/min) was
mice, fed a NC (WT n = 6; RORgt+/ n = 5) or a HFD (WT n = 6; RORgt+/ n = 7)
5) mice; glycemic index (mM/min) was calculated.
HFD n = 5) and WT (NC n = 5; HFD n = 5) mice after 30 days of HFD.
oxp3-expressing T cells (L andO) were analyzed by flow cytometry fromSILP of
ORgt/) orWTmice (Rag1/+ LTWT). (Q) Sevenweeks after transfer, IPGTT
ta are from one experiment out of three). (R) GIR was calculated during a clamp
5mice/group; data are from one experiment out of two. (T–V) Phosphorylation
leusmuscle at the end of the clamp (means ± SEM; n = 5mice/group). (W) Body
d from EchoMRI analysis. (Y) Food intake was measured over a 30 hr period.
two.
a statistically different from each other with p > 0.05.
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Figure 3. The HFD Changes Ileum Mucosa Microbiota which Affects Intestinal Immunity
(A and B) 16S rRNA gene sequencing analysis of the ileum mucosa microbiota from WT mice fed a NC (white squares) or a HFD for 10 (gray squares) or 30 days
(black squares) (n = 5 mice/group): (A) Principal Coordinate Analysis (PCoA); (B) barplot analysis on family taxons. (C and I) WT mice were fed a NC (n = 5, white
squares) or HFD and treated with saline (HFD, n = 5, black squares) or synbiotic (HFD + symbiotic, n = 5, hatch squares) for 30 days. (C and D) Ileum mucosa
microbiota16S rRNA gene sequencing analysis: (C) PCoA, (D) barplot analysis on family taxons. (E) IPGTT was performed, and the glycemic index (mM/min) was
calculated. (F) Glucose infusion rate (GIR) was calculated during a euglycemic hyperinsulinemic clamp. (G–I) Number of SILP IL17+ (G), Foxp3+ (H), and IFNg+CD4
T cells (I) were determined by flow cytometry. (E–I) All values are ± SEM; one representative experiment out of two; different superscript letters (a, b, and c) indicate
data statistically different from each other with p > 0.05. (J–O) Spearman correlation between Porphyromonadaceae (J and K), Comamonadaceae (L,M), Pep-
tostreptococcaceae (N), Bacteroidaceae (O), and relative mRNA expression of IL17 (J, L, N, and O) or RORgt (K and M) in ileum mucosa of these mice.gengivalis, a member of thePorphyromonadaceae, induces peri-
odontitis (Grover et al., 2014) and triggers IL17 production (Taka-
hashi et al., 2014). Therefore, this suggests that the reduction of
Porphyromonadaceae in the ileum at the onset of disease could
be responsible for the reduction of Th17 cells. Moreover,
an increase of Peptostreptococcaceae is associated with the
prevention from DSS-induced intestinal inflammation (Nagy-
Szakal et al., 2013), which could also contribute to the decrease
of Th17 cells.
Based on recent studies demonstrating that segmented
filamentous bacteria (SFB) in the SI favor Th17 development
(Gaboriau-Routhiau et al., 2009), we quantified the concentration
of SFB by qPCR.We showed that SFBweremuch less abundant106 Cell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc.after 10 and 30 days on HFD than in the WT NC mice
(Figure S5K). Their abundance was not restored by synbiotic
treatment. There was a similar loss of SFB from RORgt/
mice which was less pronounced inRORgt+/mice (Figure S5K).
Ivanov and colleagues (Ivanov et al., 2009) demonstrated that
Th17 cell induction by SFB was due to the release of serum am-
yloid antigen (SAA) by DCs in the gut. Therefore, we assessed
whether SAA levels in the ileum were affected in HFD-induced
disease. SAA1, SAA2, and SAA3 mRNA levels decreased after
30 days on HFD when compared to NC-fed controls (Figures
S5L–S5N). Thus, SFB and SAA are reduced in HFD-fed mice
when compared to control mice, and this correlates with the
loss of Th17 cells. Importantly, SAA3 was only restored by the
Figure 4. Microbiota of Synbiotic Treated
Mice Increases the Number of Intestinal
RORgt-Th17 Cells and Prevents Glucose
Intolerance
(A) Experimental protocol: 12-week-old axenic
mice were colonized with ileum microbiota from
HFD mice (HFD; n = 7) or with HFD/synbiotic mice
(HFD + synbiotic; n = 8).
(B) Eleven days after colonization (d11), IPGTT was
performed and glycemic index (mM/min) was
calculated.
(C–F) Numbers of SILP IL17+ (C), RORgt+ (D),
Foxp3+ (E), and IFNg+ CD4 T cells (F) were deter-
mined by flow cytometry. Graphs show means ±
SEM; different superscript letters (a, b) indicate
data statistically different from each other with
p > 0.05.synbiotic treatment, suggesting that it could rather be associated
with the improved metabolic phenotype (Figures S5L–S5N).
To investigate whether HFD-induced changes in the gut mi-
crobiota are the direct cause of the decrease in ileum Th17 cells
and metabolic disease, we colonized axenic mice with the ileum
microbiota from HFD-fed mice treated or not with synbiotic for
30 days (Figure 4A). Mice colonized with the ileum microbiota
from HFD-fed mice had higher fasting glycemia (7.5 mM) than
those colonizedwith themicrobiota from theHFD-fedmice given
the synbiotic (4.9 mM) (Figure 4B), which was similar to that of
conventional NC-fed mice (data not shown). Glucose tolerance
was lower in the mice colonized with the microbiota from HFD-
fed mice than in those colonized with HFD-fed synbiotic-treatedCell Metabolism 22, 100microbiota (Figure 4B). The effect on the
glucose tolerance was observed after
only 2 weeks of colonization and associ-
ated with a decrease in the number of
IL17/RORgt and Treg cells in the SILP
(Figures 4C–4E). The number of Th1 cells
was not statistically different in both
groups (Figure 4F). The impact of the
colonization with the ileum microbiota
was specific to the SILP, since the num-
ber of Th17 and Treg cells were similar
in the MLN from both groups of mice
(data not shown). This supports the
conclusion that these cells play a role at
the onset of metabolic disease and that
the intestinal microbiota is responsible
for the changes in intestinal immunity
observed in HFD-fed mice.
The HFD Alters the Transcriptoms
and Functions of Intestinal
Defenses
Since the above evidences indicate that a
decrease of SILP IL17/RORgt CD4 T cells
contributes to the onset of metabolic dis-
ease, we investigated the mechanisms
through which the HFD-induced changes
inmicrobiotamight cause the loss of Th17cells. First, we analyzed the transcriptomic profiles of SILP CD4
T cells of NC and HFD-fedmice. Changes in the transcriptome of
CD4 T cells were already evident after 10 days on HFD, and
some of these differences were maintained up to 30 days; other
changes appeared only after 30 days (Figure 5A). Hierarchical
clustering analysis of the transcriptomic data was able to sepa-
rate the gene expression profiles of CD4 T cells from mice fed a
HFD for 10 and 30 days and those from NC fed mice (Figure 5A).
The genes with altered expression at both 10 and 30 days on
HFDwere inflammatory genes Ifng and Sap-kinase (upregulated)
and anti-inflammatory genes such as Il27, Il18ra, and Il10 (down-
regulated). Two genes involved in CD4 T cell differentiation
(Foxp3, Gata3) were downregulated (Figure S6A). Altogether,–112, July 7, 2015 ª2015 Elsevier Inc. 107
Figure 5. The HFD Impairs the Gene Expres-
sion and the Function of SILP APCs to Pro-
mote Th17 Cell Differentiation
(A and B) Transcriptional profiles of CD4 T cells (A)
and APCs (B) from the SILP of NCmice (control; n =
10) or fed with a HFD for 10 (HFD d10; n = 10) or
30 days (HFD d30; n = 10), obtained by microarray
analysis. Heatmaps show differential gene
expression between HFD d10 versus NC and HFD
d30 and NC (with p > 0.05). Hierarchical clustering
shows the Euclidian distance between each point
of SILP CD4 T cells (A) or APCs (B) (x axis) and
between genes (y axis).
(C) Graphs show the % of CD86 on SILP DC from
NC or HFD mice.
(D and E) Cytokine production by SILP leukocytes
(CD45+ cells) from mice fed a NC or a HFD IL6 (D)
and IL12p40 (E) was assessed by ELISA.
(F andG) The%of IL17+ (F) or RORgt+ (G) OTII CD4
T cells after Th17 differentiation, with SILP cells
from NC or HFD-fed mice were graphed.
(H) The proportion of SILP TCR+CD4+RORgt+ cells
expressing Ki67 in NC or HFD-fed mice was
quantified.
(I) Quantification of Reg3b and Reg3g mRNA by
RT-qPCR of ileum frommice fed a NC, HFD d10 or
HFD d30, and synbiotic-treated HFD mice (HFD +
synbiotic).
(C–I) Graphs values are means ± SEM; n = 5 mice/
group; one representative experiment out of two;
different superscript letters (a, b) indicate data
statistically different from each other with p > 0.05.these data confirmed that HFD modified the intestinal CD4 T cell
expression profile. Since the gut microbiota regulates intestinal
immune homeostasis (Mortha et al., 2014), at least in part,
through the differentiation of Th17 cells in the SILP in an SFB
and APC-dependent manner (Goto et al., 2014), we analyzed108 Cell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc.the transcriptomic profiles of SILP APCs
which revealed broad differences in
gene expression between all groups (Fig-
ure 5B). Hierarchical clustering analysis of
the data distinguished the expression
profiles of APCs from mice fed a NC
from those of HFD-fed mice (Figure 5B).
Further analyses of the expression of
genes in APCs from mice fed a HFD for
10 or 30 days revealed upregulation of
the expression of some genes implicated
in inflammatory pathways Nfkb1, Nfx1,
Nlrp3, IL6st, and Thbs and of genes
involved in the cell stress response
psmc4, H2-1b, ffar2,3,6, and niacr1,
when compared to those of NC-fed mice
(Figure S6B). We also analyzed genes
involved in T cell costimulation and found
that icam1 and cd86were downregulated
(Figure S6B). These changes in expres-
sion of icam1 and cd86 were confirmed
by RT-qPCR of ileum mRNA (Figures
S6C and S6D). We also found lessIL12p40 mRNA in the ileum of mice after 10 and 30 days on
HFDwhen compared to NCmice (Figure S6E). To further analyze
whether the changes in mRNA levels were associated with
changes in protein concentrations, we characterized the
different subsets of SILP APCs. Their numbers were unchanged,
and neither dendritic cells nor macrophages were statistically
affected (Figures S6F–S6J). A decrease expression of the CD86
protein was seen by flow cytometry in SILP APCs after 10 and
30 days on HFD (Figure 5C). In light of the changes in gene
expression observed in APCs, we then evaluated their ability to
produce IL6 and IL12p40 (cytokines produced by APCs),
required for the differentiation and maintenance of Th17 cells,
in response to LPS in vitro. The SILP leukocytes from mice fed
a HFD for 30 days produced less IL6 and IL12p40 than NC con-
trols (Figures 5D and 5E). This impaired cytokine production
was SILP specific, since nomajor changes were observed in leu-
kocytes from theMLN (FiguresS6KandS6L) or from the IEL (data
not shown). We next evaluated the ability of SILP APCs from NC
or HFD-fed mice to induce Th17 cell differentiation. Naive CD4
T cells were cultured with SILP APCs from NC and HFD-fed
mice and with a Th17-inducing cocktail. SILP leukocytes of
mice fed a HFD for 10 or 30 days were less able to induce Th17
cells (IL17/RORgt CD4 T cells) than those from NCmice (Figures
5Fand5G).Moreover, theproportion of proliferating (Ki67+) IL17/
RORgt CD4 T cells in vivo, in the SILP, in mice after 10 or 30 days
onHFDwas lower than inNCmice (Figure 5H).Overall, thesedata
show that the HFD impaired the ability of APCs to promote Th17
cell differentiation in the ileum. In contrast to the SILP leukocytes,
those isolated from the MLN after 10 or 30 days on HFD induced
more RORgt CD4 T cells and had no effect on IL-17 production
when compared to those from NC mice (Figures S6M and
S6N). Similarly, there was no difference between the proportion
of proliferating IL17/RORgt CD4 T cells in vivo in the MLN from
NC and HFD-fed mice (Figure S6O).
Altogether, our data suggest that the loss of Th17 cells in
metabolic disease is due to an impaired APC function in the
SILP following HFD-induced changes in the microbiota. This
process would lead to a leaky gut. Further investigations are
needed to identify bacteria functions and the corresponding
mechanisms responsible for the decrease of intestinal Th17.
In order to evaluate the importance of the decrease of Th17
cells on the intestinal nonspecific defense (Ishigame et al.,
2009) during metabolic disease, we quantified mRNA level of
antimicrobial peptides Reg3b and Reg3g which are involved in
the mucosal protection. Reg3b and Reg3gwere decreased after
10 days onHFD and remained at a low level after 30 days onHFD
(Figure 5I). Synbiotic treatment prevented the decrease of both
(Figure 5I). Since metabolic disease is associated with increased
gut permeability characterized by an increased bacterial translo-
cation (Amar et al., 2011), we sequenced the 16S rRNA gene in
the MAT and found that the bacterial taxons present in HFD
mice were dramatically different from those of NC. This tissue
microbiota dysbiosis induced by HFD in the MAT (Figures 6A
and 6B) and liver (data not shown) is associated with a moderate
accumulation of Th17 cells in the liver and MAT. This could be
explained by Th17 cell migration from the SILP toward the liver
and or MAT, thereby reducing the number of Th17 cells in the in-
testine. However, this hypothesis is unlikely, since it has been
reported that the migration of T cells from the specific site of an-
tigen sensitization toward nondraining tissues was not associ-
ated, conversely to what we observed, with a reduction in the
number of T cells at the site of antigen sensitization (Ruane
et al., 2013). A most likely hypothesis is that a change in tissue
microbiota could be responsible for the recruitment of newlyactivated infiltrating Th17 cells, as shown elsewhere (Bertola
et al., 2012), to trigger metabolic inflammation. In addition, this
tissue dysbiosis was prevented by the synbiotic treatment (Fig-
ures 6A and 6B). Importantly, this feature was most likely linked
to the reduced IL17/RORgt CD4 T cells induced by the HFD,
since it was also observed in RORgt/ mice (Figures 6C and
6D) and in RORgt/ T cells transferred to Rag1 mice (Figures
6E and 6F). Our result is supported by reports showing a loss
of IL22-producing CD4 T cells in HIV-infected human subjects
(Page et al., 2014) associated with an increased bacterial trans-
location (Mavigner et al., 2012), since these patients also have a
higher incidence of T2D and lipodystrophy (Samaras, 2012).
Altogether, our findings provide the basis for a model in which
a fat-enriched diet results in specific changes in the gut micro-
biota that consequently impair the immune system of the SI by
affecting the function of APCs in the differentiation of intestinal
RORgt/Th17 cells (i.e., Th17 cells). This impaired intestinal vigi-
lance early in the course of metabolic disease leads to a change
in tissue microbiota, contributing to a later state of systemic low-
grade inflammation. This concept could provide new opportu-
nities for the prevention and treatment of metabolic disease,
including the development of treatments that may be restricted
to the intestine to avoid broad systemic deleterious effects.
EXPERIMENTAL PROCEDURES
Animal Models
Eight-week-old WT male mice were fed with a NC diet or a HFD (72%) or a
high-fat high-carbohydrate diet (HFHCD) (45%) for 30 days. For the synbiotic
treatment, mice were gavaged with polydextrose PDX with Bifidobacterium
lactis B420 (kindly provided by DuPont Nutrition & Health) or with saline for
the controls. Twelve-week-old male axenic C57Bl/6 mice were colonized
with the ileum content. Mouse genotype and diet information are reported in
Supplemental Information. All of the animal experimental procedures were
validated by the local ethical committee of the Rangueil Hospital.
RNA Extraction and Quantification
All tissues were homogenized in TRIzol (Life Technologies) and extracted.
q-PCR reactions were performed on a ViiA7 Real-Time PCR System (Life
Technologies). Data were analyzed with the ViiA7 RUO Real-Time PCR anal-
ysis software. Primer sequences are reported in Supplemental Information.
Ileum Mucosa and Adipose Tissue 16S rRNA Sequencing Analysis
The microbial population present in ileum and adipose tissue has been deter-
mined using generation high throughput sequencing of variable regions of the
16S rRNA bacterial gene (Vaiomer SAS, Labe`ge, France). PCR amplification
was performed using 16S universal primers targeting the V3-V4 region. The
detection of the sequencing fragments was performed using MiSeq Illumina
technology. More details are reported in Supplemental Information. NCBI
SRA bioproject was SUB949277 PRJNA284574.
Monitoring Metabolic Parameters
Glucose tolerance test was performed by intraperitoneal injection of glucose
(IPGTT). The glycemic index was calculated by adding the glycemic values
from all time points multiplied by the duration of the test. Plasma insulin con-
centration was assessed by ELISA (Mercodia kit). Euglycemic hyperinsuline-
mic clamps were performed at a rate of 18 mU.kg1.min1 of insulin. Body
mass composition was analyzed by quantitative nuclear magnetic resonance
(EchoMRI-100TM). For food, intake was measured during 30 hr. More details
are reported in Supplemental Information.
Liver and MAT Leukocyte Isolation
Liver (Garidou et al., 2009) and MAT (Luche et al., 2013) infiltrating leukocytes
were isolated as previously described. Liver and MAT leukocyte isolation is
described in detail in the Supplemental Information.Cell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc. 109
Figure 6. Intestinal Immunity Alteration Is Associated with Changes in Tissue Microbiota
16S rRNA gene sequencing analysis of theMATmicrobiota from (A and B) NC-fedmice (white squares), fed a HFD for 30 days (HFD) (black squares) and synbiotic
treated HFDmice (HFD + symbiotic, hatch squares) (n = 5 mice/group); (C and D) NC-fed WT (n = 5, white squares) and RORgt/ (n = 3, hatch squares) mice; (E
and F)Rag1/mice injected withWT T cells (Rag1/ + LTWT; n = 5 [white squares]) or with RORgt/ T cells (Rag1/ + LT RORgt; n = 5 [hatched squares]): (A,
C, and E) PCoA; (B, D, and F) barplot analysis on family taxons.MLN and Intestinal Leukocytes Isolation
MLN and SI were harvested and Peyer’s patches were dissected from the
SI segments. To isolate IEL, SI was incubated with EDTA. Subsequently,
fragments were incubated with collagenase and DNase to isolate leukocytes
(SILPs). The SILPs were harvested from the 70%–40% Percoll interface.
For MLN and Peyer’s patches, single-cell suspensions were prepared by110 Cell Metabolism 22, 100–112, July 7, 2015 ª2015 Elsevier Inc.mechanically disrupting. Isolation procedures are described in Supplemental
Information.
Flow Cytometry
For surface staining experiments, leukocyte suspensions were labeled
with antibodies anti-F4/80, MHCII, CD4, CD8, CD11b, CD86, TCR,
CD19, CD45, and CD11c. Cells were also stained with the LIVE∕DEAD
Fixable Cell Stain Kit (Life Technologies). Then cells were fixed, permea-
bilized, and labeled with monoclonal antibodies anti-Foxp3, RORgt,
Ki67.
For intracellular cytokine analyses, immune cells were stimulated (Maret
et al., 2003) and stained on the surface as described above. They were fixed,
permeabilized, and labeled with anti-IFNg and IL17. The labeled cell suspen-
sion was analyzed using a digital flow cytometer (LSR II Fortessa) and FlowJo
software (Tree Star). Details about antibody and labeling procedure are re-
ported in Supplemental Information.
T Cell Isolation for Adoptive Transfer
T cells were isolated from WT or RORgt/ mice, and 5 3 106 cells were in-
jected into Rag1/ mice.
Detection of Cytokines by ELISA
SILP or MLN cells were stimulated with LPS. IL-6, IL-12p40 concentrations in
supernatants were determined by ELISA. More details are reported in Supple-
mental Information.
In Vitro Th17 Differentiation
Splenic naive CD4 T cells were isolated from OTII and cultured with irradiated
MLN or SILP leukocytes with OVA peptide and a Th17 differentiation cocktail
for 5 days. IL17+ and RORgt+ CD4 T cells were analyzed by cytometry as
described above, and more details are provided in Supplemental
Information.
Western Blot Analysis
Protein of liver andmuscles were separated on gel electrophoresis, transferred
onto membrane (GE Healthcare), and hybridized with antibodies against pAkt,
Akt, pNFkB p65, NFkB p65, pGSK-3b, GSK-3b, and GAPDH. Immunoblots
were revealed by enhanced chemiluminescence (BIO-RAD). Antibody refer-
ences are reported in Supplemental Information.
Microarray Analysis of Intestinal CD4+ T Cells and APCs
CD4+ T cells and APCs from the SILP were sorted (Influx, Becton Dickinson).
RNA was extracted, amplified and expression profiling was performed by
Miltenyi Genomic Services (Miltenyi Biotec, Paris, France) using the Agilent
Microarray (Miltenyi Biotec). More details are provided in Supplemental
Information.
Data Analysis
Data were analyzed by using Microsoft Excel, and graphs were done by
GraphPad Prism. Statistical significance (p < 0.05) was determined by using
a Student’s t test, Mann-Whitney, Kruskal-W.
ACCESSION NUMBERS
NCBI GEO accession numbers are as follows: GSE52557, GSE52558,
GSE52559.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article at http://dx.doi.org/10.1016/j.
cmet.2015.06.001.
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